This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F et al. Sleep disordered breathing and cardiovascular disease. Cross sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19–25.
McNicholas WT, Bonsignore MR, and the Management Committee of EU COST ACTION B 26. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007; 29 (1): 156–178.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: a statement for healthcare professionals from the Centres for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511.
Cooke JP . Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109: 813–818.
Tsioufis C, Thomopoulos K, Dimitriadis K, Amfilochiou A, Tousoulis D, Alchanatis M et al. The incremental effect of obstructive sleep apnoea syndrome on arterial stiffness in newly diagnosed essential hypertensive subjects. J Hypertens 2007; 25 (1): 141–146.
Ohayon M, Guilleminault C . Sleep disordered breathing and C reactive protein: a commentary. Sleep 2007; 30: 679.
Punjami NM, Beamer BA . C-reactive protein is associated with sleep disordered breathing independent of adiposity. Sleep 2007; 30: 29–34.
Shamsuzzaman AS, Winnicki M, Lafranchi P, Wolk R, Kara T, Accurso V et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462–2464.
Drager L, Bortolotto L, Lorenzi MC, Figueiredo A, Krieger E, Lorenzi-Filho G . Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 613–618.
Miyazaki H, Matsuoka H, Cooke J, Usui M, Ueda S, Okuda S et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141–1146.
Ohike Y, Kozaki K, Eto M, Kojima T, Ohga E, Santa T et al. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure. Possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circ J 2005; 69: 221–226.
Tsioufis C, Stougiannos P, Kakkavas A, Toutouza M, Mariolis A, Vlasseros I et al. Relation of left ventricular concentric remodelling to the levels of C-reactive protein and serum amyloid-A in patients with essential hypertension. Am J Cardiol 2005; 96 (2): 252–256.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thomopoulos, C., Tsioufis, C., Dimitriadis, K. et al. Obstructive sleep apnoea syndrome is associated with enhanced sub-clinical inflammation and asymmetric dimethyl-arginine levels in hypertensives. J Hum Hypertens 23, 65–67 (2009). https://doi.org/10.1038/jhh.2008.101
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2008.101
This article is cited by
-
Association between tumor necrosis factor alpha and obstructive sleep apnea in adults: a meta-analysis update
BMC Pulmonary Medicine (2020)
-
Roles of interleukin (IL)-6 gene polymorphisms, serum IL-6 levels, and treatment in obstructive sleep apnea: a meta-analysis
Sleep and Breathing (2016)
-
The ‘pyrrhic victory’ of amlodipine over hydrochlorothiazide in the OLAS Study
Journal of Human Hypertension (2011)